Member Info for Tornadotony

Sitting on my hands to see if it goes how I think its trying to play out. Will then add to the 129 hold and average down the 315 once we have some chart data that is useful (different accounts). The LSE is the cause of all the volatility. MOEX and USA are hardly moving about at all. Its us lot that are probably causing the swings by our interventions. Turned into a bitcoin playground. Should call it poly coin.

Top end is around 350p. I suspect 265-268p where it has bounced a couple of times may be the bottom end. The value of Kaz is dependent on prevailing gold price which Berenberg have not gone into. At 1920 per ounce 325p would be a good estimate. All just an opinion before I get told off.

All the action is in London market we had a high volume at start. Will probably add another buy to average off entry. USA market closed at 327p area.

320p buy is in.

Correct a few comments.

1. If you go to the Synairgen website you will find that back in 2003 the founders of the company were at the University of Southampton Biobank (one of 5) funded by MRC, Welcome Trust and Dept of Health. So the academics supporting Synairgen knew the importance of bio banking especially if you want to hunt for biomarkers that are predictive of healthcare outcomes where the genetics of an individual affects their response to disease. A number of cancer drugs that require particular pathology tests to find patient specific biomarkers aid prescribing for their treatment now currently exist thanks to the creation of these entities.

2. It was in the protocol to freeze a blood sample, probably after centrifugation to keep at -40C in a freezer if it were possible. Every major hospital will have freezers around the globe. The problem is whether they were supplied with a device that could deliver all the frozen samples taken and get them back to the UK as if it was an organ for a transplant. The local pathology lab would have needed payment to do it. So it would have cost money to do it and for somebody to collect it at the airport and get it down to Southampton and have it stored. To me it was always a possibility that to spend £2,000 on antiviral treatment that you may need laboratory tests to say who would benefit from the nebuliser beta interferon and who may not do so. If a lab test costs £40 and the numbers tested was 1 in 3 of those being prescribed it was well doing in having the prescription of treatment followed out in this way.

3. The company ran behind on their protocol schedule on patient numbers so the pressure was to recruit and make it easy as possible. In doing so collecting blood specimens for storage was sacrificed. It was basically seen as a hurdle in getting the recruitment done. Hindsight tells us that it may have been better if the results came out six months later and things did not get rushed, however omicron may have reduced the impact of Synairgen's treatment. In essence the ultimate failure was the company was just too small to deliver a clinical trial at the speed of a major big pharma company and it could not do it all in-house with staff facilitating the back up of having bio banked samples being collected.

4. To a degree this is not the fault of a CEO between a rock and a hard place. My disappointment was thinking it was being done and it wasn't. If it had been done I would not have sold any synairgen shares as the answer could have been in the samples collected as to why more fatalities were arising in the placebo group. A market of 10 people out of 600 in hospital is still a sizeable market in a pandemic. As Seaboy mentioned every hospital would have 4 or 5 doses of Synairgen's product in medicines store.

Aether

Its a long shot if they could put a host of trial results together and applied as an orphan drug therapy as its market use would be limited.
The trial could not go on forever. One serious problem was issuing an RNS that an employee spouse bought shares. as it did more harm than good. They should have just sold them and we knew nothing about it. This was a huge mistake in retrospect. The only complaint I have was for a company based within a Biobank facility that it did not have the intelligence to insist that a Biobank sample was to go back to the company and that whatever costs they ensured it was done. The company would now be sitting on a treasure trove of blood samples that would unlock why it survived more lives and hence what test needed to be done to save those at risk patients. All the best and we live and all learn. Stay well and I wish everyone better luck in future.

Billy

I am an expert in the healthcare field. I knew that the trial results would not be as good as the first trial. The key Billy was that the company did not secure a frozen blood sample from 610 people and secured its arrival back to Synairgen. If they had done so the company could have identified a laboratory test that would indicate when the Synairgen drug could be prescribed and save lives. The company was based in a Biobank facility. I was devasted when I found they had not done this routinely as the protocol was based on best efforts. These things happen hence why we have different investment baskets.

To Billy wild
1. In the future never put all your investments in one share. Its rule number 1 is to have investments in many different baskets such as equities, bonds, valuables and one day housing.
2. Learn about trading share volatility. Some of us who arrived after July 2020 built up 50% of our shares from profits by selling high and buying it back lower which is rule number 2. Some of us have wasted time here at Synairgen from losing in the end on many winning trades, but our losses are half of those investors who bought late on and never traded and had a high average price.
3. Everybody has a losing year occasionally. Your not married to any equity stock. I am not throwing more money at Synairgen. I have kept 7.5% of my original holding only to manage it out as a loss next year. Instead rule number 3, do research into what else you would like to read about and learn the subject matter like an expert. If you do not have a clue what it is do not put your money into it. Only you can be in charge of where you put your funds. Double check and cross reference what you can. You examine competition. You identify what is good value and what is overpriced. You find out the quality of people in what you are investing in. You understand accounts and read through risk management documents public companies provide in annual reports and so forth.
4. As others have said you are young, but now wiser. It is how you come back from your set back and use this disappointment to motivate yourself in being far better on whatever you choose to do. The skills you pick up are resilience , risk management and attention to detail and much more.

Ramp something might be up as Moex was falling back when it was leading the way up past two days. As for Massive Ray's comment, I was very careful what I wrote on SNG and I always emphasised or acknowledged the limitations of technical charts. Yes I know there are price differences across Polymetal charts.

Unless folks are selling for CGT reasons, I am not sure why RBWR is pulling back.

Over 5% down with support lines breaking. Interesting to see if UK and USA follow.

Managed to regain it but its weaker support position.

It may get it back, first breach in awhile. We may get some volatility soon.

Try again later.

Rebought small position. Will average down if it goes lower. USA close was near 372p.

Thanks dogstar I should have read it more carefully.

The annual report is due around next week before Easter. The first quarter report was planned week commencing 25 April. The AGM is late.

Await another retreat. 129p entry continues.

Finally get the results from the lab.

Another RNS on schedule.